A Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Adult Patients with Chronic Spontaneous Urticaria Inadequately Controlled by H1 Antihistamines
Latest Information Update: 27 Dec 2024
At a glance
- Drugs RPT 904 (Primary) ; Omalizumab
- Indications Chronic urticaria
- Focus Therapeutic Use
- Sponsors Jemincare
Most Recent Events
- 23 Dec 2024 According to RAPT Therapeutics media release,topline data from this trial is expected in the first half of 2026.
- 28 Nov 2024 Status changed from not yet recruiting to recruiting.
- 25 Jul 2024 New trial record